Lisata Therapeutics Inc. Reports Recent Stock Performance

Lisata Therapeutics, Inc., a biopharmaceutical company specializing in cardiovascular and autoimmune disease treatments, has recently experienced notable stock activity. As of May 6, 2025, the company’s stock closed at $2.30 on the Nasdaq, reflecting a significant movement within the biotechnology sector of the health care industry.

The company’s stock has seen fluctuations over the past year, with a 52-week high of $4.20 recorded on January 5, 2025. Conversely, the stock reached a 52-week low of $1.87 on April 6, 2025. These movements highlight the volatility often associated with biotechnology firms, particularly those in the early stages of product development.

Lisata Therapeutics operates globally, serving a diverse customer base worldwide. The company’s focus on developing innovative treatments for cardiovascular and autoimmune diseases positions it as a key player in the biotechnology industry. Despite the challenges, the company continues to pursue its mission of advancing healthcare solutions.

As of the latest financial data, Lisata Therapeutics has a market capitalization of $20,760,000 USD. The company’s price-to-earnings ratio stands at -1, indicating that it is not currently generating profits. This is not uncommon for companies in the biotechnology sector, where significant investments in research and development can precede profitability.

For more information about Lisata Therapeutics and its product offerings, interested parties can visit the company’s website at www.caladrius.com . The company remains committed to its mission of developing cutting-edge therapies to address unmet medical needs in cardiovascular and autoimmune diseases.